Phase I/II 90 Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma
Year: 2000
Type: article
Study design: Clinical Trial
Authors: Gregory A. Wiseman, Christine A. White, Michael Stabin, William L. Dunn, William Erwin, Magnus Dahlbom, Andrew Raubitschek, Kastytis Karvelis, Timothy Schultheiss, Thomas E. Witzig, Richard Belanger, Stewart Spies, Daniel H. S. Silverman, Judy R. Berlfein, Eric Ding, Antonio J. Grillo-López
Institutions: Mayo Clinic, Biogen (United States), Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, University of California, Los Angeles, City Of Hope National Medical Center, City of Hope, Henry Ford Health, Henry Ford Hospital, Fox Chase Cancer Center
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2080416356